- HAI/KEI intervention at the WHA69 on the Framework of Engagement with Non-State Actors
- WHA69: Draft resolution (A69/B/CONF./7) on CEWG follow-up charts course for WHO's work on R&D
- WHO to Colombia Minister of Health: Unaffordable drug prices are a legitimate reason for issuing a compulsory license
- 28 Organizations Ask President Obama to Support Colombian Compulsory License on Expensive Leukemia Drug
- HAI/KEI intervention at the WHA69 on the negotiations on an R&D agreement
- Sens. Sherrod Brown and Bernie Sanders send letter to USTR condemning pressure on Colombia compulsory license for cancer drug
- 15 House Dems Press USTR to Clarify Position on Compulsory Licensing of cancer drug patent in Colombia
- Senator Hatch Defends Pressure on Colombia in Interview Regarding Imatinib
- WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies
- Letter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License
USPTO White Paper Suggests Statutory Factors To Clarify Extent of Statutory Damages for Copyright InfringementSubmitted by Salvatore Angotti on 10. February 2016 - 14:13
By Salvatore Angotti*
On February 8, 2016, the National Institutes of Health (NIH) responded to Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment’s (UACT) letter requesting that the federal government exercise its authority under the Bayh-Dole Act to break patents on an expensive prostate cancer drug.
In May 2014, the 67th World Health Assembly (WHA) of the World Health Organization (WHO) passed Decision WHA67(15) providing WHO the mandate to explore the feasibility of creating a voluntary pooled fund fund on R&D hosted by the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). The Decision outlined three principles guiding the consideration of the pooled fund:
Implications of the Trans Pacific Partnership (TPP) and Regional Comprehensive Economic Partnership (RCEP) on Universal Health Coverage
Knowledge Ecology International
26 January 2016
9 AM to 12:30 PM
Lotus Suite 3. 22nd Floor
Bangkok Convention Centre
Today Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) petitioned the Department of Health and Human Services, the Department of Defense, and the National Institutes of Health, asking that they exercise either their royalty-free, non-exclusive license or federal "march-in" rights to end the monopoly on an expensive prostate cancer drug, enzalutamide, marketed as Xtandi by Astellas, a Japanese pharmaceutical company.
Xtandi was invented at UCLA on federal grants from the NIH and DoD.
Knowledge Ecology International joins amicus brief on non-copyrightability of model laws and statutesSubmitted by KEI Staff on 13. January 2016 - 11:14
Washington, DC — On January 11, 2016, Knowledge Ecology International joined Public Knowledge and the American Library Association in an amicus curiae brief that argued that the contents of model laws, once enacted into statute, cannot be protected by copyright. The brief was filed with the U.S. District Court for the District of Columbia in the case of ASTM International v. Public.Resource.Org.
This was the release from Representative Doggett's office:
FOR IMMEDIATE RELEASE
January 11, 2016
Leslie Tisdale, (202) 225-4865
Over 50 Members of Congress to Obama Administration:
Help End Drug Price Gouging Now
WHO's evaluation of the global strategy and plan of action on public health, innovation and intellectual propertySubmitted by thiru on 11. January 2016 - 4:36
In May 2008, the 61st World Health Assembly (WHA) of the World Health Organization (WHO) adopted the seminal global strategy and plan of action on public health, innovation and intellectual property.
As stated in its aim, the global strategy on public health, innovation and intellectual property serves to
In calendar year 2015, FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs). This is a large number of approvals.
Attached here is a KEI submission to the US ITC for the January hearing of the
UNITED STATES INTERNATIONAL TRADE COMMISSION
Investigation No. TPA-105-001
Trans-Pacific Partnership Agreement: Likely Impact on the U.S. Economy and on Specific Industry Sectors
Our earlier, related testimony on trade agreements was here: http://keionline.org/node/2370
Under the UK's Pharmaceutical Price Regulation Scheme (PPRS), drug companies will make rebates of about £550 million in 2016, according to this story.
SAVE THE DATE - 16 December 2015 - KEI breakout session on A WTO Agreement on the Supply of Social GoodsSubmitted by thiru on 15. December 2015 - 6:45
On Wednesday, 16 December 2015, at the Fourth Global Congress on Intellectual Property and the Public Interest (National Law University, Delhi, India), Knowledge Ecology International (KEI) will convene a breakout session (led by Jamie Love, Director, KEI) on a WTO Agreement on the Supply of Social Goods.
MICHELE WOODS: Standing Committee on Copyright and Related Rights, 31st session, Geneva, December 7 to 11, 2015. Summary by the Chair.
Agenda item 1. Opening of the session. The 31st session of the Standing Committee on Copyright and Related Rights SCCR or Committee was opened by Mr. Francis Gurry, Director General who welcomed the participants and opened agenda item 2.
Ms. Michele Woods, WIPO, acted as secretary.
The Chair proposed an intersessional on broadcasting and regional meetings regarding Libraries and Archives. This was supported by Asia, Grulac and Africa (but Africa wanted to include education and research institution) and rejected by Group B. The decision will be made at the next SCCR, SCCR 32 possibly May 9-13 2016.
Day 5 of SCCR 31, December 11, 2015
We welcome the proposal tabled by Senegal and the Congo to include the droit de suite, the artist resale right, in this Committee’s agenda for future work.
I would like to refer to the Directive mentioned by the Commission, Directive 2001/84/EC which came into force on 1 January 2006: